Browsing by Author "Kuper-Hommel, Marion"

Now showing items 1-4 of 4

  • The characteristics, management and outcomes of older women with breast cancer in New Zealand

    Blackmore, Tania Louise; Lawrenson, Ross; Lao, Chunhuan; Edwards, Melissa; Kuper-Hommel, Marion; Elwood, Mark; Campbell, Ian (Elsevier, 2018)
    The aim of this study was to understand the characteristics of older women with breast cancer and to describe the current patterns of treatment and outcomes. The study included data from the combined Auckland and Waikato ...
  • Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study

    Elwood, J. Mark; Tin Tin, Sandar; Kuper-Hommel, Marion; Lawrenson, Ross; Campbell, Ian (BMC, 2018)
    Background: Obesity has been reported as an adverse prognostic factor in breast cancer, but inconsistently, and under-treatment with chemotherapy may occur. We provide the first assessment of obesity and breast cancer ...
  • Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes

    Lawrenson, Ross; Lao, Chunhuan; Campbell, Ian; Harvey, Vernon; Seneviratne, Sanjeewa; Edwards, Melissa; Elwood, Mark; Scott, Nina; Kidd, Jacquie; Sarfati, Diana; Kuper-Hommel, Marion (Springer, 2017)
    Purpose This study aims to look at the distribution of different subtypes of stage I–III breast cancer in Māori and Pacific versus non-Māori/Pacific women, and to examine cancer outcomes by ethnicity within these different ...
  • The use of trastuzumab in New Zealand women with breast cancer

    Lawrenson, Ross; Lao, Chunhuan; Campbell, Ian; Harvey, Vernon; Brown, Charis; Seneviratne, Sanjeewa; Edwards, Melissa; Elwood, Mark; Kuper-Hommel, Marion (Wiley, 2017)
    Aim Trastuzumab was first funded in New Zealand for use in HER2+ve stage I–III breast cancer in 2007. This observational study aims to ascertain the patterns of use of trastuzumab in women with invasive HER2+ve breast ...